Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetaminophen + codeine + caffeine is a fixed-dose combination oral analgesic containing three active ingredients: - **Acetaminophen** (also known as paracetamol) is an analgesic and antipyretic that works by inhibiting prostaglandin synthesis in the central nervous system to reduce pain and fever. - **Codeine** is an opioid agonist that acts primarily on the mu-opioid receptor in the brain and spinal cord to provide pain relief through inhibition of ascending pain pathways. - **Caffeine** is a central nervous system stimulant that enhances the analgesic effect of acetaminophen and counteracts drowsiness caused by codeine. This combination is used for short-term relief of mild to moderate pain when other non-opioid treatments are inadequate or not tolerated. Caffeine may also help improve alertness and increase the effectiveness of analgesics[8]. The product carries risks associated with opioids (addiction, abuse, misuse), hepatotoxicity from excessive acetaminophen use, and potential side effects from caffeine such as insomnia or palpitations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + codeine + caffeine.